RG7834 NEW
| Price | $31 |
| Package | 1mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-12 |
Product Details
| Product Name: RG7834 | CAS No.: 2072057-17-9 |
| Purity: 99.88% | Supply Ability: 10g |
| Release date: 2026/06/12 |
Product Introduction
Bioactivity
| Name | RG7834 |
| Description | RG7834 (RO 7020322) is a highly selective and orally bioavailable inhibitor of HBV, targeting HBsAg, HBeAg, and HBV DNA with IC50s of 2.8 nM, 2.6 nM, and 3.2 nM, respectively, in dHepaRG Cells. |
| In vitro | RG7834 ((S)-(+)-64) is a highly selective and orally bioavailable inhibitor of HBV, potently inhibiting HBV antigens (HBsAg and HBeAg) and HBV DNA with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG cells. RG7834 exhibits no activity against CYP3A4, CYP2D6, CYP2C9 (IC50s >50 μM) or the hERG channel. |
| In vivo | In HBV-infected human liver chimeric uPA-SCID mice,RG7834 shows anti-HBV efficacy. RG7834 (2, 14.5 mg/kg, p.o.) exhibits good oral bioavail ability, and with a half-life of 4.9 h in mice. |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.96 mM), Sonication is recommended. DMSO : 140 mg/mL (348.74 mM), Sonication is recommended. |
| Keywords | RO-7020322 | RO7020322 | RG-7834 | RG7834 | RG 7834 | Inhibitor | inhibit | Hepatitis B virus | HBV DNA | HBV | HBsAg | HBeAg |
| Inhibitors Related | Doxorubicin hydrochloride | Famciclovir | Lamivudine | Cetylpyridinium Chloride | Tenofovir Disoproxil Fumarate | Estradiol benzoate | Thiamine hydrochloride | (Tetrahydro-2H-pyran-4-yl)methanol | Adefovir | 4-Hydroxyacetophenone | Nicotinamide | Tenofovir |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $31.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY